PMID- 20704823
OWN - NLM
STAT- MEDLINE
DCOM- 20101207
LR  - 20211020
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 13
IP  - 8
DP  - 2010 Aug
TI  - [Clinical investigation of efficacy of pemetrexed in 32 patients with pulmonary 
      adenocarcinoma after failure to chemotherapy and gefitinib].
PG  - 809-12
LID - 10.3779/j.issn.1009-3419.2010.08.11 [doi]
AB  - BACKGROUND AND OBJECTIVE: The relapse-free time of gefitinib as the second or 
      third line therapy in patients with advanced non-small cell lung cancer (NSCLC) 
      was not satisfactory. The aim of this study is to evaluate the efficacy and 
      toxicity of pemetrexed in patients with pulmonary adenocarcinoma after failure to 
      chemotherapy and gefitinib. METHODS: A total of 32 relapsed patients with 
      pulmonary adenocarcinoma after failure to chemotherapy and gefitinib received 
      pemetrexed 500 mg/m2 by the intravenous administration on the first day, with 21 
      days as a cycle. Dexamethasone, folic acid and vitamin B12 were applied to 
      relieve the drug toxicity. The objective response rate was estimated by Response 
      Evaluation Criteria in Solid Tumors (RECIST) and the toxicity was estimated by 
      National Cancer Institute Common Toxicity Criteria (version 3.0). RESULTS: For a 
      total of 32 patients, 4 patients reached partial response (PR), constituting a 
      total of 12.5%; 11 patients reached stable disease (SD), constituting a total of 
      34.4%; 17 patients reached progressive disease (PD), constituting a total of 
      53.1%. The median progression free survival (PFS) was 2.7 months. The median 
      overall survival (OS) was 11.0 months. One-year survival rate was 37.5%. The most 
      common adverse events (AEs) were myelosuppression with grade I and grade II 
      toxicity. Other adverse events were tolerated. CONCLUSION: Pemetrexed was 
      clinically beneficial for the patients with pulmonary adenocarcinoma after the 
      failure of chemotherapy and gefitinib.
FAU - Wu, Biao
AU  - Wu B
AD  - Department of Medical Oncology, Fujian Provincial Tumor Hospital, Fujian Medical 
      University Educational Hospital, Fuzhou 350014, China.
FAU - Huang, Cheng
AU  - Huang C
FAU - Jiang, Kan
AU  - Jiang K
FAU - Zhuang, Wu
AU  - Zhuang W
FAU - Xu, Zhenwu
AU  - Xu Z
FAU - Zhang, Jing
AU  - Zhang J
LA  - chi
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Glutamates)
RN  - 0 (Quinazolines)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 5Z93L87A1R (Guanine)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality
MH  - Disease-Free Survival
MH  - Female
MH  - Gefitinib
MH  - Glutamates/*administration & dosage/adverse effects
MH  - Guanine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Pemetrexed
MH  - Quinazolines/therapeutic use
MH  - Survival Rate
MH  - Treatment Failure
MH  - Treatment Outcome
PMC - PMC6000551
EDAT- 2010/08/14 06:00
MHDA- 2010/12/14 06:00
PMCR- 2010/08/20
CRDT- 2010/08/14 06:00
PHST- 2010/08/14 06:00 [entrez]
PHST- 2010/08/14 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
PHST- 2010/08/20 00:00 [pmc-release]
AID - zgfazz-13-8-809 [pii]
AID - 10.3779/j.issn.1009-3419.2010.08.11 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2010 Aug;13(8):809-12. doi: 
      10.3779/j.issn.1009-3419.2010.08.11.